Geode Capital Management LLC Purchases New Shares in Rapport Therapeutics (NASDAQ:RAPP)

Geode Capital Management LLC purchased a new position in Rapport Therapeutics (NASDAQ:RAPP) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 201,748 shares of the company’s stock, valued at approximately $4,133,000. Geode Capital Management LLC owned approximately 0.55% of Rapport Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Values First Advisors Inc. purchased a new position in Rapport Therapeutics during the 3rd quarter valued at about $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Rapport Therapeutics during the third quarter worth approximately $34,000. SG Americas Securities LLC purchased a new position in Rapport Therapeutics during the third quarter valued at approximately $101,000. Sandia Investment Management LP acquired a new position in Rapport Therapeutics in the 2nd quarter valued at approximately $116,000. Finally, MetLife Investment Management LLC acquired a new position in Rapport Therapeutics in the 3rd quarter valued at approximately $117,000.

Rapport Therapeutics Stock Up 5.9 %

RAPP opened at $19.48 on Monday. The company’s fifty day moving average price is $21.51. Rapport Therapeutics has a 1 year low of $16.55 and a 1 year high of $29.74.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.